AI Telephone

John Smith is a 45-year-old man with confirmed, active type 2 diabetes mellitus, diagnosed last month; the exact diagnosis date was not provided. He has an active prescription for metformin 500 mg twice daily with meals for treatment of his diabetes. His latest HbA1c is 7.8%, and his BMI is 28 kg/m²; both results are finalized. He has no known drug allergies.

John Smith is a 45-year-old male with type 2 diabetes mellitus diagnosed on October 1, 2023. He is currently prescribed metformin 500mg twice daily with meals. Laboratory results from October 15, 2023 show a hemoglobin A1c of 7.8% and a BMI of 28 kg/m².

Clinical Narrative

John Smith is a male patient born in 1980 with an active patient record. He has no known drug allergies, and this status is active and confirmed.

Mr. Smith was diagnosed last month with type 2 diabetes mellitus without complications (SNOMED CT 44054006; ICD-10-CM E11.9). The diagnosis is active and confirmed and is recorded on his problem list. It is supported by a hemoglobin A1c of 7.8% (LOINC 4548-4), which is flagged as high relative to the normal reference range of below 5.7%. This laboratory result is final.

His body mass index is 28 kg/m², which is flagged as high and interpreted as overweight. This vital sign result is final.

For his type 2 diabetes, he has an active order for metformin hydrochloride 500 mg oral tablets (RxNorm 861007). He is to take 500 mg by mouth twice daily with meals.

No appointments or scheduling information are included in this record.

John Smith is a 45-year-old male with a confirmed diagnosis of Type 2 Diabetes Mellitus, diagnosed last month (exact date not provided). His latest hemoglobin A1c is 7.8%. He has a BMI of 28 kg/m². He is currently prescribed metformin 500 mg twice daily with meals. He has no known drug allergies.

John Smith is a male born in 1980 with an active patient record. He has a confirmed, active encounter diagnosis of type 2 diabetes mellitus without complications (ICD-10-CM E11.9), documented as diagnosed “last month.” A finalized hemoglobin A1c result of 7.8%, flagged as high, is cited as supporting evidence for the diagnosis. His finalized BMI measurement is 28 kg/m². An active prescription for metformin hydrochloride 500 mg oral tablets was ordered for diabetes management, with instructions to take 500 mg by mouth twice daily with meals; additional instructions specify taking it with or after food. His allergy record is active and confirmed and documents no known drug allergies.

Clinical Narrative

John Smith is a male patient born on January 1, 1978 (patient identifier 12345). He has no known allergies.

On October 1, 2023, when he was 45 years old, Mr. Smith was diagnosed with type 2 diabetes mellitus. The diagnosis is confirmed and the condition remains active. On the same day, he was prescribed metformin 500 mg oral tablets, taken by mouth at a dose of 500 mg twice daily with meals. The prescription is active.

On October 15, 2023, two weeks after diagnosis, his hemoglobin A1c was 7.8% and his body mass index was 28 kg/m². Both results are final.

Coding Discrepancies

• Medication code: The medication is coded as RxNorm 314076, but the display reads "Metformin 500 MG Oral Tablet." RxNorm 314076 corresponds to lisinopril 10 MG oral tablet. The standard RxNorm code for metformin 500 MG oral tablet is 861007. This narrative follows the display text and dosage instructions, which both indicate metformin, but the code should be verified.
• Allergy code: The allergy entry displays "No known allergy" but uses SNOMED CT code 232347008. That code does not match the standard SNOMED CT concept for "No known allergy," which is 716186003. The code should be verified to confirm that the patient truly has no known allergies.